Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
roche
9
×
san francisco blog main
9
×
san francisco top stories
boston blog main
boston top stories
biotech
cancer
clinical trials
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
investing
amgen
merck
novartis
president trump
biogen
blueprint medicines
cancer immunotherapy
eli lilly
What
drug
9
×
cancer
roundup
bio
fda
medicines
approval
blueprint
genetic
latest
new
patients
plan
pricing
ret
targets
today
acquisitions
address
advanced
advantages
ahead
albert
alzheimer’s
ambien
american
annual
approved
approves
arrival
asco
attendees
attention
award
bar
biggest
biotech
bourla
brings
camp’s
Language
unset
unknown
Current search:
drug
×
" san francisco blog main "
×
roche
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More